Metabolic and toxicological considerations of botanicals in anticancer therapy

Bibliography

• WHO. Cancer Fact Sheet N°297. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ [Last accessed 7 February 2012]
   Google Scholar
• Aggarwal BB, Sethi G, Baladandayuthapani V, Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 2007;102:580-92
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Owzar K, Corless CL, Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Gili M, Scaltriti M, Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221-30
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology. Nat Biotechnol 2007;25:1110-11
   PubMed Web of Science ®Google Scholar
• Klijn JG, Beex LV, Mauriac L, Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000;92:903-11
   PubMed Web of Science ®Google Scholar
• Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8
   PubMed Web of Science ®Google Scholar
• Bellido M, Te Boekhorst PA. JAK2 inhibition: reviewing a new therapeutical option in myeloproliferative neoplasms. Adv Hematol 2012; doi:10.1155/2012/535709
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91
   PubMed Web of Science ®Google Scholar
• Morgan MA, Reuter CWM. Molecularly targeted therapies in myelodysplastic sindrome and acute myeloid leucemia. Ann Hematol 2006;85:139-63
   PubMed Web of Science ®Google Scholar
• Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 2011;12:122-32
   PubMed Web of Science ®Google Scholar
• Chen ST, Dou J, Temple R, New therapies from old medicines. Nat Biotechnol 2008;26:1077-83
   PubMed Web of Science ®Google Scholar
• Feng Y, Wang N, Zhu M, Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Pat Food Nutr Agric 2011;3:30-48
   PubMedGoogle Scholar
• Melzer J, Iten F, Hostanska K, Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementarmed 2009;16:217-26
   Web of Science ®Google Scholar
• Karmakar S, Choudhury SR, Banik NL, Diederich M. Molecular mechanisms of anti-cancer action of garlic compounds in neuroblastoma. Anticancer Agents Med Chem 2011;11:398-407
   PubMed Web of Science ®Google Scholar
• Cheon J, Kim J, Lee J, Use of garlic extract as both preventive and therapeutic agents for human prostate and bladder cancers. US6465020; 2002
   Google Scholar
• Pai MH, Kuo YH, Chiang EP, Tang FY. S-Allylcysteine inhibits tumour progression and the epithelial-mesenchymal transition in a mouse xenograft model of oral cancer. Br J Nutr 2011;20:1-11
   Google Scholar
• Shukla Y, Singh M. Cancer preventive properties of ginger: a brief review. Food Chem Toxicol 2007;45:683-90
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Leppert JT, Zomorodian N, Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12:4018-26
   PubMed Web of Science ®Google Scholar
• Albrecht M, Jiang W, Kumi-Diaka J, Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004;7:274-83
   PubMed Web of Science ®Google Scholar
• Managoli N. Herbo-mineral formulation for refractory leukaemias and lymphomas. US20050058722; 2005
   Google Scholar
• Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phytomedicine-ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 2009;16:2924-42
   PubMed Web of Science ®Google Scholar
• Shim JY, Han Y, Ahn JY, Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-treated normal and tumor bearing mice. Int J Immunopathol Pharmacol 2007;20:487-97
   PubMed Web of Science ®Google Scholar
• Spelman K, Aldag R, Hamman A, Traditional herbal remedies that influence cell adhesion molecule activity. Phytother Res 2011;25:473-83
   PubMed Web of Science ®Google Scholar
• Shin HR, Kim JY, Yun TK, The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control 2000;11:565-76
   PubMed Web of Science ®Google Scholar
• Kim JH, Park CY, Lee SJ. Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. J Clin Pharm Ther 2006;31:331-4
   PubMed Web of Science ®Google Scholar
• Cui Y, Shu XO, Gao YT, Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 2006;163:645-53
   PubMed Web of Science ®Google Scholar
• Manusirivithaya S, Sripramote M, Tangjitgamol S, Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer 2004;14:1063-9
   PubMed Web of Science ®Google Scholar
• Ryan JL, Heckler CE, Roscoe JA, Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 2011; DOI: 10.1007/s00520-011-1236-3
   Web of Science ®Google Scholar
• Xu AH, Chen HS, Sun BC, Therapeutic mechanism of ginkgo biloba exocarp polysaccharides on gastric cancer. World J Gastroenterol 2003;9:2424-7
   PubMed Web of Science ®Google Scholar
• Hauns B, Haring B, Kohler S, Phase II study with 5-fluorouracil and Ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancer. Arzneimittelforschung 1999;49:1030-4
   PubMed Web of Science ®Google Scholar
• Hauns B, Haring B, Kohler S, Phase II study of combined 5-fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. Phytother Res 2001;15:34-8
   PubMed Web of Science ®Google Scholar
• Lam W, Bussom S, Guan F, The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010;18:45ra59
   Google Scholar
• Alsamarai S, Ravage-Mass L, Kaley K, A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors. J Clin Oncol 2010;28:e13571
   Google Scholar
• Yen Y, So S, Rose M, Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res 2009;29:4083-92
   PubMed Web of Science ®Google Scholar
• Eng C. Are herbal medicines ripe for the cancer clinic? Sci Transl Med 2010;2:45ps41
   PubMedGoogle Scholar
• Dewick PM. The biosynthesis of C5-C25 terpenoid compounds. Nat Prod Rep 1997;14:111-44
   PubMed Web of Science ®Google Scholar
• Wagner H. Antihepatotoxic flavonoids. Prog Clin Biol Res 1986;213:545-58
   PubMedGoogle Scholar
• Bokemeyer C, Fels LM, Dunn T, Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer 1996;74:2036-41
   PubMed Web of Science ®Google Scholar
• Mansour HH, Hafez HF, Fahmy NM. Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. J Biochem Mol Biol 2006;39:656-61
   PubMedGoogle Scholar
• Singh RP, Tyagi A, Sharma G, Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 2008;14:300-8
   PubMed Web of Science ®Google Scholar
• Singh RP, Raina K, Deep G, Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signalling. Clin Cancer Res 2009;15:613-21
   PubMed Web of Science ®Google Scholar
• Flaig TW, Gustafson DL, Su LJ, A Phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139-46
   PubMed Web of Science ®Google Scholar
• Hoh C, Boocock D, Marczylo T, Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 2006;12:2944-50
   PubMed Web of Science ®Google Scholar
• Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006;45:436-42
   PubMed Web of Science ®Google Scholar
• Singh RP, Deep G, Blouin MJ, Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 2007;28:2567-74
   PubMed Web of Science ®Google Scholar
• Schroder FH, Roobol MJ, Boeve ER, Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005;48:922-30
   PubMed Web of Science ®Google Scholar
• Ulbricht C, Chao W, Costa D, Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008;9:1063-120
   PubMed Web of Science ®Google Scholar
• Mazzio EA, Soliman KF. In vitro screening for the tumoricidal properties of international medicinal herbs. Phytother Res 2009;23:385-98
   PubMed Web of Science ®Google Scholar
• Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009;11:28-79
   Google Scholar
• Matthes H, Friedel WE, Bock PR, Zanker KS. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med 2010;10:430-9
   PubMed Web of Science ®Google Scholar
• Finall AI, McIntosh SA, Thompson WD. Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract. BMJ 2006;333:1293-4
   PubMed Web of Science ®Google Scholar
• Ernst E. Mistletoe as a treatment for cancer. BMJ 2006;333:1282-3
   PubMed Web of Science ®Google Scholar
• Huber R, Klein R, Berg PA, Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects. J Altern Complement Med 2002;8:857-66
   PubMed Web of Science ®Google Scholar
• Hallek M. Interleukin-6-mediated cell growth in multiple myeloma - a role for Viscum album extracts? Onkologie 2005;28:387
   PubMed Web of Science ®Google Scholar
• Huber R, Ludtke H, Wieber J, Beckmann C. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. BMC Complement Altern Med 2011;11:116
   PubMedGoogle Scholar
• Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005;5:447-58
   PubMed Web of Science ®Google Scholar
• Kaivosaari S, Finel M, Koskinen M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica 2011;41:652-69
   PubMed Web of Science ®Google Scholar
• Colalto C. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol Res 2010;62:207-27
   PubMed Web of Science ®Google Scholar
• Wen Z, Dumas TE, Schrieber SJ, Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008;36:65-72
   PubMed Web of Science ®Google Scholar
• Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro 2011;25:21-7
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76:428-40
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci 2006;78:2105-15
   PubMed Web of Science ®Google Scholar
• Sridar C, Goosen TC, Kent UM, Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32:587-94
   PubMed Web of Science ®Google Scholar
• Van Erp NP, Baker SD, Zhao M, Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005;11:7800-6
   PubMed Web of Science ®Google Scholar
• Jacob DA, Mercer SL, Osheroff N, Deweese JE. Etoposide quinone is a redox-dependent topoisomerase II poison. Biochemistry 2011;50:5660-7
   PubMed Web of Science ®Google Scholar
• Reif S, Nicolson MC, Bisset D, Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 2002;58:491-4
   PubMed Web of Science ®Google Scholar
• Perdaems N, Caunes N, Canal P, Chatelut E. Possible excretion of etoposide via the intestinal mucosa. Cancer Chemother Pharmacol 1999;43:520-1
   PubMed Web of Science ®Google Scholar
• Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 1998;21:1062-6
   PubMed Web of Science ®Google Scholar
• Soldner A, Christians U, Susanto M, Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1998;16:478-85
   Web of Science ®Google Scholar
• Li F, Desai PB, Harris JW. Modulation of hepatic and intestinal CYP3A4 and P-gp expression and activity by BAS 100, a naturally occurring bioavailability-boosting agent from grapefruit juice. Drug Metab Rev 2006;38(Suppl 2):116
   Google Scholar
• Smith NF, Baker SD, Gonzalez FJ, Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 2008;98:1630-2
   PubMed Web of Science ®Google Scholar
• McKillop D, McCormick AD, Millar A, Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005;35:39-50
   PubMed Web of Science ®Google Scholar
• Engdal S, Nilsen OG. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 2009;23:906-12
   PubMed Web of Science ®Google Scholar
• Engdal S, Nilsen OG. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008;38:559-73
   PubMed Web of Science ®Google Scholar
• Doehmer J, Eisenbraun J. Assessment of extracts from mistletoe (Viscum album) for herb-drug interaction by inhibition and induction of cytochrome P450 activities. Phytother Res 2012;26:11-27
   PubMed Web of Science ®Google Scholar
• Haber D, Siess MH, De Waziers I, Modification of hepatic drug-metabolizing enzymes in rat fed naturally occuring allyl sulphides. Xenobiotica 1994;24:169-82
   PubMed Web of Science ®Google Scholar
• Foster BC, Foster MS, Vandenhoek S, An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001;4:176-84
   PubMed Web of Science ®Google Scholar
• Hajda J, Rentsch KM, Gubler C, Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010;41:729-35
   PubMed Web of Science ®Google Scholar
• Makhov P, Golovine K, Canter D, Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity. Prostate 2012;72:661-7
   PubMed Web of Science ®Google Scholar
• Fu Y, Li S, Zu Y, Medicinal chemistry of paclitaxel and its analogues. Curr Med Chem 2009;16:3966-8
   PubMed Web of Science ®Google Scholar
• Cox MC, Low J, Lee J, Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006;12:4636-40
   PubMed Web of Science ®Google Scholar
• Komoroski BJ, Parise RA, Egorin MJ, Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 2005;11:6972-9
   PubMed Web of Science ®Google Scholar
• Shukla PC, Singh KK, Yanagawa B, DNA damage repair and cardiovascular diseases. Can J Cardiol 2010;26(Suppl A):13A-6A
   Google Scholar
• Khan AO. Genetics of primary glaucoma. Curr Opin Ophthalmol 2011;22:347-55
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Quaegebeur A, Vikkula M, Carmeliet P. Cerebrovascular disorders: molecular insights and therapeutic opportunities. Nat Neurosci 2011;14:1390-7
   PubMed Web of Science ®Google Scholar
• FDA. Botanical Drug Products Guidance. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); Rockville: 2004
   Google Scholar
• EMEA. Concept Paper on Selection of Test Materials for Genotoxicity Testing for Traditional Herbal Medicinal Products/Herbal Medicinal Products-An Annex to Guideline on the Assessment of Genotoxicity of Herbal Substances/Preparations Draft. European Medicines Agency; London: 2008
   Google Scholar
• Van den Berg SJPL, Restani P, Boersma MG, Levels of genotoxic and carcinogenic compounds in plant food supplements and associated risk assessment. Food Nutr Sci 2011;2:989-1010
   Google Scholar
• Zhou SF, Xue CC, Yu XQ, Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 2007;8:526-53
   PubMed Web of Science ®Google Scholar
• Lee HS, Seo EY, Kang NE. Kim WK. [6]-Gingerol inhibits metastasis of MDAMB-231 human breast cancer cells. J Nutr Biochem 2008;19:313-19
   PubMed Web of Science ®Google Scholar
• Yang G, Zhong L, Jiang L, Genotoxic effect of 6-gingerol on human hepatoma G2 cells. Chem Biol Interact 2010;185:12-17
   PubMed Web of Science ®Google Scholar
• Angeli JP, Barcelos GR, Serpeloni JM, Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2). Mutagenesis 2010;25:223-9
   PubMed Web of Science ®Google Scholar
• Burlinson B. The in vitro and in vivo comet assays. Methods Mol Biol 2012;817:143-63
   PubMedGoogle Scholar
• Kirsch-Volders M, Plas G, Elhajouji A, The in vitro MN assay in 2011: origin and fate, biological significance, protocols, high throughput methodologies and toxicological relevance. Arch Toxicol 2011;85:873-99
   PubMed Web of Science ®Google Scholar
• Stopper H, Schmitt E, Kobras K. Genotoxicity of phytoestrogens. Mutat Res 2005;574:139-55
   PubMed Web of Science ®Google Scholar
• Caria H, Chaveca T, Laires A, Rueff J. Genotoxicity of quercetin in the micronucleus assay in mouse bone marrow erythrocytes, human lymphocytes, V79 cell line and identification of kinetochore-containing (crest staining) micronuclei in human lymphocytes. Mutat Res 1995;343:85-94
   PubMed Web of Science ®Google Scholar
• Crebelli R, Aquilina G, Falcone E, Carere A. Urinary and faecal mutagenicity in Sprague Dawley rats dosed with the food mutagens quercetin and rutin. Food Chem Toxicol 1987;25:9-15
   PubMed Web of Science ®Google Scholar
• Harwood M, Danielewska-Nikiel B, Borzelleca JF, A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45:2179-205
   PubMed Web of Science ®Google Scholar
• Utesch D, Feige K, Dasenbrock J, Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res 2008;654:38-44
   PubMed Web of Science ®Google Scholar
• Sanchez-Lamar A, Fonseca G, Fuentes JL, Assessment of the genotoxic risk of Punica granatum L. (Punicaceae) whole fruit extracts. J Ethnopharmacol 2008;115:416-22
   PubMed Web of Science ®Google Scholar
• EFSA. Compendium of Botanicals that have been reported to Contain Toxic, Addictive, Psychotropic or Other Substances of Concern. European Food Safety Authority; Parma: 2009
   Google Scholar
• Basaran AA, Yu TW, Plewa MJ, Anderson D. An Investigation of some Turkish herbal medicines in Salmonella typhimurium and in the COMET assay in human lymphocytes. Teratogen Carcinog Mutagen 1996;16:125-38
   PubMedGoogle Scholar
• Wu KM, Dou J, Ghantous H, Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A. Regul Toxicol Pharmacol 2010;56:1-3
   PubMed Web of Science ®Google Scholar